Anbio Biotechnology (NNNN)

NASDAQ: NNNN · Real-Time Price · USD
7.75
-0.05 (-0.64%)
May 22, 2025, 4:00 PM - Market closed
-0.64%
Market Cap 340.16M
Revenue (ttm) 8.19M
Net Income (ttm) 2.37M
Shares Out 43.89M
EPS (ttm) 0.06
PE Ratio 138.13
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 39,393
Open 7.80
Previous Close 7.80
Day's Range 7.62 - 8.22
52-Week Range 5.18 - 8.20
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About NNNN

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021... [Read more]

Sector Healthcare
IPO Date Feb 19, 2025
Employees 27
Stock Exchange NASDAQ
Ticker Symbol NNNN
Full Company Profile

Financial Performance

In 2024, Anbio Biotechnology's revenue was $8.19 million, an increase of 21.95% compared to the previous year's $6.71 million. Earnings were $2.37 million, an increase of 5.29%.

Financial numbers in USD Financial Statements

News

Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions

Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Collaboration Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Coll...

8 days ago - GlobeNewsWire

U.S. IPO Weekly Recap: IPO Calendar Slows Down With Small Listings

The calendar slowed down this past week, with only small listings in the US. There was one sizable filing this past week - AIRO Group Holdings. No IPOs are currently scheduled to list in the week ahea...

Other symbols: AURNKMTSODTXONEWGRX
3 months ago - Seeking Alpha

Anbio Biotechnology Announces Closing of Initial Public Offering

Frankfurt am Main, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the “Company” or “Anbio”), a global diagnostic company dedicated to the advancement of medical technology and the pro...

3 months ago - GlobeNewsWire

Anbio Biotechnology Announces Pricing of Initial Public Offering

Frankfurt am Main, Germany, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the “Company” or “Anbio”), a global diagnostic company dedicated to the advancement of medical technology and the pro...

3 months ago - GlobeNewsWire

U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings

Two small IPOs listed this week - INLIF and OneConstruction Group. Five issuers and two SPACs submitted initial filings this week. The 2025 IPO market is here, and while there are a few small deals on...

4 months ago - Seeking Alpha

Anbio Biotechnology Pursues U.S. IPO For Its IVD Products Launch

Anbio Biotechnology plans to raise $8.8 million in an IPO to commercialize its in vitro diagnostics products amid market risks. The company has experienced fluctuating revenue and profitability, with ...

5 months ago - Seeking Alpha

Anbio Biotechnology IPO Registration Document (F-1)

Anbio Biotechnology has filed to go public with an IPO on the NASDAQ.

5 months ago - SEC